Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia

Primary Objective: Cohort 1A: To determine the recommended phase 2 dose (RP2D) of ziftomenib in combination with quizartinib and assess the safety and the maximum tolerated dose (MTD). Secondary Objectives: To assess the preliminary efficacy of the combination of quizartinib and ziftomenib by FLT3 mutational status. To assess overall survival (OS), relapse-free survival (RFS), event-free survival (EFS) and duration of response (DOR). To characterize the pharmacokinetic profile of ziftomenib and quizartinib when used in combination. To assess minimal residual disease negativity by flow cytometry.